Literature DB >> 22314195

Usefulness of Choline-PET for the detection of residual hemangiopericytoma in the skull base: comparison with FDG-PET.

Shin Ito1, Junkichi Yokoyama, Hitoshi Yoshimoto, Masaki Yazawa, Kubota Kazuo, Makoto Hanaguri, Shinichi Ohba, Mitsuhisa Fujimaki, Katsuhisa Ikeda.   

Abstract

BACKGROUND: Choline is a new PET tracer that is useful for the detection of malignant tumor. Choline is a precursor of the biosynthesis of phosphatidylcholine, a major phospholipid in the cell membrane of eukaryotic cells. Malignant tumors have an elevated level of phosphatidylcholine in cell membrane. Thus, choline is a marker of tumor malignancy.
METHOD: The patient was a 51-year-old man with repeated recurrent hemangiopericytoma in the skull base. We performed Choline-PET in this patient after various treatments and compared findings with those of FDG-PET.
RESULTS: Choline accumulated in this tumor, but FDG did not accumulate. We diagnosed this tumor as residual hemangiopericytoma and performed the resection of the residual tumor. FDG-PET is not appropriate for skull base tumor detection because uptake in the brain is very strong.
CONCLUSION: We emphasize the usefulness of Choline-PET for the detection of residual hemangiopericytoma in the skull base after various treatments, compared with FDG-PET.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22314195      PMCID: PMC3297510          DOI: 10.1186/1746-160X-8-3

Source DB:  PubMed          Journal:  Head Face Med        ISSN: 1746-160X            Impact factor:   2.151


  8 in total

1.  HEMANGIOPERICYTOMA: A VASCULAR TUMOR FEATURING ZIMMERMANN'S PERICYTES.

Authors:  A P Stout; M R Murray
Journal:  Ann Surg       Date:  1942-07       Impact factor: 12.969

2.  Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET.

Authors:  T Hara; K Inagaki; N Kosaka; T Morita
Journal:  J Nucl Med       Date:  2000-09       Impact factor: 10.057

3.  Brain tumors: detection with C-11 choline PET.

Authors:  N Shinoura; M Nishijima; T Hara; T Haisa; H Yamamoto; K Fujii; I Mitsui; N Kosaka; T Kondo; T Hara
Journal:  Radiology       Date:  1997-02       Impact factor: 11.105

4.  PET imaging of brain tumor with [methyl-11C]choline.

Authors:  T Hara; N Kosaka; N Shinoura; T Kondo
Journal:  J Nucl Med       Date:  1997-06       Impact factor: 10.057

5.  Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging.

Authors:  O Kobori; Y Kirihara; N Kosaka; T Hara
Journal:  Cancer       Date:  1999-11-01       Impact factor: 6.860

6.  Hemangiopericytoma. Report of a case and comprehensive review of the literature.

Authors:  K D Backwinkel; J A Diddams
Journal:  Cancer       Date:  1970-04       Impact factor: 6.860

7.  Hemangiopericytoma. An analysis of 106 cases.

Authors:  F M Enzinger; B H Smith
Journal:  Hum Pathol       Date:  1976-01       Impact factor: 3.466

8.  PET imaging of prostate cancer using carbon-11-choline.

Authors:  T Hara; N Kosaka; H Kishi
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

  8 in total
  4 in total

1.  F18-fluorodeoxyglucose positron emission tomography/computed tomography for bone hemangiopericytoma.

Authors:  Yiyan Liu
Journal:  Mol Clin Oncol       Date:  2017-10-18

Review 2.  Molecular imaging of brain tumors with radiolabeled choline PET.

Authors:  Ferdinando Franco Calabria; Manlio Barbarisi; Vincenzo Gangemi; Giovanni Grillea; Giuseppe Lucio Cascini
Journal:  Neurosurg Rev       Date:  2016-05-26       Impact factor: 3.042

Review 3.  Hemangiopericytoma/solitary fibrous tumor of the cranial base: a case series and literature review.

Authors:  Zhouying Peng; Yumin Wang; Yaxuan Wang; Qinxuan Li; Yan Fang; Ruohao Fan; Hua Zhang; Weihong Jiang
Journal:  BMC Surg       Date:  2022-07-27       Impact factor: 2.030

Review 4.  Intracranial Solitary Fibrous Tumor: A "New" Challenge for PET Radiopharmaceuticals.

Authors:  Angela Sardaro; Paolo Mammucci; Antonio Rosario Pisani; Dino Rubini; Anna Giulia Nappi; Lilia Bardoscia; Giuseppe Rubini
Journal:  J Clin Med       Date:  2022-08-14       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.